Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19458170 | 0.74 | MEN1 (0.39) | MEN1APOBEC3ARAB9AKMT2AAPOBEC3G | |
| Bromide SCHEMBL38657137 | 0.69 | HDAC8 (0.41) | TDP1 | |
| SCHEMBL19458168 | 0.65 | SMN1; SMN2 (0.36) | TDP1TP53CYP3A4THRBALOX15 | |
| SCHEMBL29729219 | 0.63 | — | — | |
| P-Xylene SCHEMBL28187926 | 0.62 | IDO1 (0.55) | MEN1KMT2AKCNH2TDP1TP53 | |
| SCHEMBL5497395 | 0.62 | IDO1 (0.55) | MEN1KMT2AKCNH2TDP1TP53 | |
| SCHEMBL40574 | 0.62 | — | — | |
| SCHEMBL16075983 | 0.62 | MEN1 (0.33) | MEN1NPC1GAAAPOBEC3ARAB9A | |
| Bromide SCHEMBL19063544 | 0.62 | HDAC8 (0.44) | NPC1RAB9AKCNH2TP53SMN1; SMN2 | |
| Iodide SCHEMBL14633634 | 0.62 | HDAC8 (0.44) | MEN1APOBEC3ARAB9AKMT2AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3232455-B1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR ELECTRIC DOUBLE LAYER CAPACITORS | OTSUKA CHEMICAL CO LTD (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-20230276690-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) | 2023-08-31 | — | — | US | disclosed |
| US-10914987-B2 | Complex and optical element | KYOTO UNIVERSITY (JP) | 2021-02-09 | — | — | US | disclosed |
| US-20200241336-A1 | COMPLEX AND OPTICAL ELEMENT | KYOTO UNIVERSITY (JP) | 2020-07-30 | — | — | US | disclosed |
| US-10593488-B2 | Nonaqueous electrolytic solution for electric double layer capacitors | OTSUKA CHEMICAL CO., LTD. (JP) | 2020-03-17 | — | — | US | disclosed |
| US-20170330700-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR ELECTRIC DOUBLE LAYER CAPACITORS | OTSUKA CHEMICAL CO., LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| EP-3232455-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR ELECTRIC DOUBLE LAYER CAPACITORS | Otsuka Chemical Co., Ltd. (JP) | 2017-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230276690-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | L1CAM, TELO2, LIMS1 | MEN1 1446/4885NPC1 4334/4885GAA 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.